“Supports metabolism” is a broad claim. For someone with prediabetes or diabetes, the important questions are more specific: does a product improve glucose control, reduce complications, or change the need for treatment?
Human studies of NAD precursors have produced mixed metabolic findings. An improvement in a laboratory measure of muscle insulin sensitivity is not the same as reversing diabetes, and it does not establish a benefit from NAD+ injections.
The metabolic research is interesting but limited. Do not replace diabetes medicines or monitoring with an NAD product.
What did the NMN study show?
A 2021 randomized trial studied 25 postmenopausal women with prediabetes and overweight or obesity over ten weeks. NMN improved a specialized measure of muscle insulin sensitivity and related signaling. This was a narrow population and a mechanistic endpoint. The result is not evidence that NMN cures diabetes, produces general weight loss, or has the same effects in men, younger people, or people using a different NAD product.
What did an NR trial find?
A 2018 placebo-controlled study enrolled 40 sedentary men with obesity and insulin resistance. Twelve weeks of NR did not improve insulin sensitivity or the reported glucose-metabolism measures. This does not erase the NMN finding, but it prevents treating every NAD precursor as one proven metabolic therapy. Ingredient, population, and study design all changed between the trials.
Why an insulin-sensitivity result is not a treatment outcome
Research can measure how muscle responds during a controlled laboratory procedure. Day-to-day care also asks about glucose readings, A1C, symptoms, medication effects, and longer-term health. A study needs to measure the outcome behind the claim. If a seller moves directly from a cellular pathway to a promise of diabetes reversal, ask for the actual human trial supporting that step.
A blend can introduce a different glucose question
Some NAD-support products also contain niacin. The NIH niacin fact sheet notes that high-dose nicotinic acid can raise glucose and interfere with diabetes management. This is a warning about that ingredient and exposure, not proof that NR, NMN, or direct NAD all have the same effect. Bring the complete label to a pharmacist; the front-panel phrase “NAD support” is not enough for an interaction review.
What should stay in place?
The NIDDK diabetes guide describes individualized care involving medicines when needed, monitoring, nutrition, and activity. Continue the plan agreed with your healthcare team unless that team changes it. Do not reduce prescribed medication because an NAD reading improved or a supplement advertisement describes insulin signaling.
Questions to take to an appointment
Ask whether the study population matches you, what clinical outcome a proposed product is expected to change, and whether its other ingredients require monitoring. For a combined GLP-1 offer, distinguish evidence for the prescribed drug from evidence for added NAD. See NAD and weight loss, combination injections, and medication interactions.
Sources & reading notes
Primary sources checked September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Yoshino et al. (2021): NMN and muscle insulin sensitivity Small randomized study in postmenopausal women with prediabetes; not evidence for NAD injections or general weight loss.
- Dollerup et al. (2018): NR metabolic trial in men with obesity 40 men, 12 weeks; no improvement in insulin sensitivity or reported glucose-metabolism measures.
- NIH Office of Dietary Supplements: niacin Nutritional and biochemical context; not a clinical trial of NAD+ injections.
- NIDDK: managing diabetes Established care context; no endorsement of NAD products as diabetes treatment.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.